RU2020103379A - Новые молекулы нуклеиновых кислот - Google Patents
Новые молекулы нуклеиновых кислот Download PDFInfo
- Publication number
- RU2020103379A RU2020103379A RU2020103379A RU2020103379A RU2020103379A RU 2020103379 A RU2020103379 A RU 2020103379A RU 2020103379 A RU2020103379 A RU 2020103379A RU 2020103379 A RU2020103379 A RU 2020103379A RU 2020103379 A RU2020103379 A RU 2020103379A
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- acid molecule
- sequence
- artificial nucleic
- rna
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title claims 54
- 102000039446 nucleic acids Human genes 0.000 title claims 54
- 150000007523 nucleic acids Chemical class 0.000 title claims 54
- 239000002773 nucleotide Substances 0.000 claims 30
- 125000003729 nucleotide group Chemical group 0.000 claims 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 22
- 239000012634 fragment Substances 0.000 claims 20
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 229960005486 vaccine Drugs 0.000 claims 16
- 108091026890 Coding region Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 230000000890 antigenic effect Effects 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 125000002091 cationic group Chemical group 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 4
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 4
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 4
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 4
- 108010033040 Histones Proteins 0.000 claims 4
- -1 RPSAP58 Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 4
- 229940029575 guanosine Drugs 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 102000014914 Carrier Proteins Human genes 0.000 claims 3
- 108010078791 Carrier Proteins Proteins 0.000 claims 3
- 108091028075 Circular RNA Proteins 0.000 claims 3
- 108020004705 Codon Proteins 0.000 claims 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 210000000170 cell membrane Anatomy 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 230000002538 fungal effect Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 108091008875 B cell receptors Proteins 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 101150077194 CAP1 gene Proteins 0.000 claims 2
- 102100021992 CD209 antigen Human genes 0.000 claims 2
- 102100038077 CD226 antigen Human genes 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 108020004635 Complementary DNA Proteins 0.000 claims 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 2
- RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- 102100023125 Mucin-17 Human genes 0.000 claims 2
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 claims 2
- 108091007412 Piwi-interacting RNA Proteins 0.000 claims 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 2
- 102100038358 Prostate-specific antigen Human genes 0.000 claims 2
- 206010037075 Protozoal infections Diseases 0.000 claims 2
- 102000039471 Small Nuclear RNA Human genes 0.000 claims 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 claims 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims 2
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 2
- 108020004566 Transfer RNA Proteins 0.000 claims 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 238000011374 additional therapy Methods 0.000 claims 2
- 150000003838 adenosines Chemical class 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 108020004418 ribosomal RNA Proteins 0.000 claims 2
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 1
- 101001015038 Albizia kalkora Kunitz-type trypsin inhibitor alpha chain Proteins 0.000 claims 1
- 102100026882 Alpha-synuclein Human genes 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 241000180579 Arca Species 0.000 claims 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims 1
- 101710117995 B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims 1
- 101710203996 CD226 antigen Proteins 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 102000049320 CD36 Human genes 0.000 claims 1
- 108010045374 CD36 Antigens Proteins 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102100025933 Cancer-associated gene 1 protein Human genes 0.000 claims 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 claims 1
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 102100039788 GTPase NRas Human genes 0.000 claims 1
- 108091006109 GTPases Proteins 0.000 claims 1
- 102400000921 Gastrin Human genes 0.000 claims 1
- 108010052343 Gastrins Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000933825 Homo sapiens Cancer-associated gene 1 protein Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims 1
- 101001027631 Homo sapiens Kinesin-like protein KIF20B Proteins 0.000 claims 1
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 claims 1
- 101001036406 Homo sapiens Melanoma-associated antigen C1 Proteins 0.000 claims 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 claims 1
- 101000623904 Homo sapiens Mucin-17 Proteins 0.000 claims 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 1
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 claims 1
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 claims 1
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 claims 1
- 101000798076 Homo sapiens T cell receptor delta constant Proteins 0.000 claims 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims 1
- 102100037691 Kinesin-like protein KIF20B Human genes 0.000 claims 1
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 claims 1
- 101710134369 Kinesin-like protein KIF2C Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 claims 1
- 102100030417 Matrilysin Human genes 0.000 claims 1
- 108090000855 Matrilysin Proteins 0.000 claims 1
- 102100039447 Melanoma-associated antigen C1 Human genes 0.000 claims 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 claims 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 101710155095 Mucin-17 Proteins 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 101150073096 NRAS gene Proteins 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 1
- 102100031574 Platelet glycoprotein 4 Human genes 0.000 claims 1
- 101710202087 Platelet glycoprotein 4 Proteins 0.000 claims 1
- 108091036407 Polyadenylation Proteins 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 108010007568 Protamines Proteins 0.000 claims 1
- 102000007327 Protamines Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 108020004422 Riboswitch Proteins 0.000 claims 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 1
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 claims 1
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 claims 1
- 102100032272 T cell receptor delta constant Human genes 0.000 claims 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 1
- 101710191252 T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 1
- 101710098414 Tyrosine-protein phosphatase Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 102000040856 WT1 Human genes 0.000 claims 1
- 108700020467 WT1 Proteins 0.000 claims 1
- 101150084041 WT1 gene Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000006978 adaptation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 1
- 229920006317 cationic polymer Polymers 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 238000011354 first-line chemotherapy Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 108091027963 non-coding RNA Proteins 0.000 claims 1
- 102000042567 non-coding RNA Human genes 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 229920002851 polycationic polymer Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 229940048914 protamine Drugs 0.000 claims 1
- 238000011127 radiochemotherapy Methods 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000011333 second-line chemotherapy Methods 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
- 230000001573 trophoblastic effect Effects 0.000 claims 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
- 229940045145 uridine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y503/00—Intramolecular oxidoreductases (5.3)
- C12Y503/03—Intramolecular oxidoreductases (5.3) transposing C=C bonds (5.3.3)
- C12Y503/03012—L-Dopachrome isomerase (5.3.3.12)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2017/066676 | 2017-07-04 | ||
| EPPCT/EP2017/066676 | 2017-07-04 | ||
| PCT/EP2018/068015 WO2019008001A1 (en) | 2017-07-04 | 2018-07-03 | NEW NUCLEIC ACID MOLECULES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020103379A true RU2020103379A (ru) | 2021-08-04 |
| RU2020103379A3 RU2020103379A3 (https=) | 2021-12-07 |
Family
ID=59384128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020103379A RU2020103379A (ru) | 2017-07-04 | 2018-07-03 | Новые молекулы нуклеиновых кислот |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10988754B2 (https=) |
| EP (3) | EP3424524B1 (https=) |
| JP (2) | JP7722629B2 (https=) |
| KR (1) | KR102761594B1 (https=) |
| CN (1) | CN111328287A (https=) |
| AU (1) | AU2018298422B2 (https=) |
| BR (1) | BR112019028280A2 (https=) |
| CA (1) | CA3066932A1 (https=) |
| ES (1) | ES3013993T3 (https=) |
| RU (1) | RU2020103379A (https=) |
| SG (1) | SG11201911430PA (https=) |
| WO (1) | WO2019008001A1 (https=) |
Families Citing this family (191)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| CN104114572A (zh) * | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| RU2658490C2 (ru) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| RU2718988C2 (ru) | 2013-02-22 | 2020-04-15 | Куревак Аг | Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| BR112016001192A2 (pt) | 2013-08-21 | 2017-08-29 | Curevac Ag | Vacina contra a raiva |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
| DE202015010000U1 (de) | 2014-12-12 | 2023-07-03 | CureVac SE | Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| KR102643923B1 (ko) | 2014-12-23 | 2024-03-05 | 이매틱스 바이오테크놀로지스 게엠베하 | 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 |
| DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
| PL4108769T3 (pl) | 2015-05-29 | 2024-02-05 | CureVac Manufacturing GmbH | Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| US11225682B2 (en) | 2015-10-12 | 2022-01-18 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| US11413346B2 (en) | 2015-11-09 | 2022-08-16 | Curevac Ag | Rotavirus vaccines |
| PE20230343A1 (es) | 2015-12-11 | 2023-03-01 | Immatics Biotechnologies Gmbh | Peptidos que estimulan respuestas inmunitarias antitumorales |
| EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
| EP3394280A1 (en) | 2015-12-23 | 2018-10-31 | CureVac AG | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| US11723967B2 (en) | 2016-02-17 | 2023-08-15 | CureVac SE | Zika virus vaccine |
| EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| EP4233898A3 (en) | 2016-05-04 | 2023-11-01 | CureVac SE | Influenza mrna vaccines |
| EP4631970A3 (en) | 2016-05-04 | 2026-01-07 | CureVac SE | Nucleic acid molecules and uses thereof |
| WO2017212009A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
| WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3551230A1 (en) | 2016-12-08 | 2019-10-16 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
| EP3558356A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
| WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
| AU2018240515B2 (en) | 2017-03-24 | 2024-07-25 | CureVac SE | Nucleic acids encoding CRISPR-associated proteins and uses thereof |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| CN108728477B (zh) * | 2017-04-24 | 2022-02-22 | 华东理工大学 | 一种高效的转座突变系统及构建方法 |
| WO2018211038A1 (en) | 2017-05-17 | 2018-11-22 | Curevac Ag | Method for determining at least one quality parameter of an rna sample |
| EP4467196A3 (en) * | 2017-06-28 | 2025-06-25 | The Cleveland Clinic Foundation | Treatment of nervous system injury and neurodegenerative disorders and related conditions |
| RU2020103379A (ru) * | 2017-07-04 | 2021-08-04 | Куревак Аг | Новые молекулы нуклеиновых кислот |
| CR20200059A (es) * | 2017-07-07 | 2020-06-01 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| EP3707271A1 (en) | 2017-11-08 | 2020-09-16 | CureVac AG | Rna sequence adaptation |
| EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
| EP3728634A1 (en) | 2017-12-21 | 2020-10-28 | CureVac AG | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
| CA3091558A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| BR112020025601A8 (pt) | 2018-06-28 | 2022-07-05 | Tesla Automation GmbH | Biorreator para a transcrição in vitro de rna |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| TW202039534A (zh) * | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| US12492425B2 (en) | 2018-12-21 | 2025-12-09 | CureVac SE | Methods for RNA analysis |
| EP3683229A1 (en) * | 2019-01-21 | 2020-07-22 | Charité - Universitätsmedizin Berlin | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy |
| CN111466338B (zh) * | 2019-01-23 | 2022-03-22 | 中国科学院广州生物医药与健康研究院 | Ddx5基因缺失的生精障碍小鼠模型及其构建方法 |
| US20220177891A1 (en) * | 2019-02-19 | 2022-06-09 | Board Of Regents, The University Of Texas System | Hipk inhibitors and methods of use thereof |
| CN109777783B (zh) * | 2019-02-20 | 2023-07-04 | 上海尚泰生物技术有限公司 | 表达cxcr2的car-nk92细胞、制备方法及其应用 |
| CN111620934B (zh) * | 2019-02-26 | 2022-03-08 | 中国科学院遗传与发育生物学研究所 | 蛋白GmHSFB2b在调控植物黄酮类化合物积累中应用 |
| CN110093419B (zh) * | 2019-04-26 | 2023-10-27 | 北京大学深圳医院 | 环状rna的应用、试剂盒和药物组合物及其应用 |
| US12448450B2 (en) | 2019-07-04 | 2025-10-21 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Method for treating tumor using anti-CTLA4 single-domain antibodies |
| CN112175062B (zh) * | 2019-07-05 | 2022-07-15 | 中国医学科学院基础医学研究所 | Sft2b蛋白线性抗原表位以及其在精神分裂症诊断中的用途 |
| EP4022069A4 (en) * | 2019-08-28 | 2023-12-20 | The Board of Trustees of the Leland Stanford Junior University | MODIFIED CIRCULAR RNAS AND METHOD OF USE THEREOF |
| EP4048316A1 (en) * | 2019-10-21 | 2022-08-31 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
| JP2023505737A (ja) * | 2019-12-11 | 2023-02-10 | アベリノ ラボ ユーエスエー インコーポレイテッド | Ｒ１２４ｈ突然変異を備えたトランスフォーミング増殖因子ベータ誘導遺伝子の短鎖干渉ｒｎａを使用したアレル特異的サイレンシング |
| KR20220121246A (ko) | 2019-12-20 | 2022-08-31 | 큐어백 아게 | 핵산 전달용 신규한 지질 나노입자 |
| CN111057690A (zh) * | 2019-12-23 | 2020-04-24 | 维塔恩(广州)医药有限公司 | 肿瘤相关基因braf突变相关抗原短肽及其应用 |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| CN111118011B (zh) * | 2020-02-11 | 2022-09-06 | 昆明医科大学 | 一种抑制hsa_circ_0027478表达的siRNA及其应用 |
| CN111733158B (zh) * | 2020-02-11 | 2022-09-06 | 昆明医科大学 | 一种抑制hsa_circ_0003599表达的siRNA及其应用 |
| CN111647597B (zh) * | 2020-02-11 | 2022-09-06 | 昆明医科大学 | 一种抑制hsa_circ_0027479表达的siRNA及其应用 |
| CN111647598B (zh) * | 2020-02-11 | 2022-09-06 | 昆明医科大学 | 一种抑制hsa_circ_0027477表达的siRNA及其应用 |
| CN111337678B (zh) * | 2020-02-21 | 2023-06-06 | 杭州凯保罗生物科技有限公司 | 与肿瘤免疫治疗效果相关的生物标志物及其应用 |
| EP4132576A1 (en) | 2020-04-09 | 2023-02-15 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
| KR20230034333A (ko) | 2020-07-02 | 2023-03-09 | 라이프 테크놀로지스 코포레이션 | 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도 |
| CN111840303A (zh) * | 2020-07-15 | 2020-10-30 | 天津大学 | 胞质羧肽酶抑制剂及其应用 |
| CN111984622B (zh) * | 2020-07-31 | 2023-10-31 | 上海派拉软件股份有限公司 | Pap的配置及运行方法、装置、电子设备和存储介质 |
| US20230346921A1 (en) * | 2020-08-21 | 2023-11-02 | Peking University | Circular rna vaccines and methods of use thereof |
| CN112011564A (zh) * | 2020-09-04 | 2020-12-01 | 西南大学 | 新型隐球菌细胞核指示载体及其构建方法和应用 |
| CN111973745B (zh) * | 2020-09-08 | 2022-07-26 | 中国医科大学 | Bap18在乳腺癌内分泌治疗抵抗中的应用 |
| CN114225035B (zh) * | 2020-09-09 | 2022-12-16 | 上海交通大学医学院 | 环状RNA Cwc27下调剂在制备预防和/或治疗阿尔茨海默病的药物中的应用 |
| DE102020125457A1 (de) * | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| CN112574975B (zh) * | 2020-09-30 | 2022-04-01 | 华南理工大学 | 甘油酯脂肪酶突变体g28c-p206c及其编码基因与应用 |
| CN112050201B (zh) * | 2020-10-10 | 2022-04-12 | 清华大学 | 一种异型炉膛结构的湍动流化床焚烧炉 |
| CN112190719B (zh) * | 2020-10-19 | 2023-07-04 | 重庆大学 | 一种钙调控机制紊乱的动物模型在视网膜病变中的应用 |
| CN112375766B (zh) * | 2020-12-02 | 2022-04-29 | 华南农业大学 | 一种水稻抗氧化能力相关基因brhis1及其应用 |
| CN112480232B (zh) * | 2020-12-14 | 2022-07-15 | 上海交通大学 | 一种生物活性肽vsladlqndevafr及其制备方法和应用 |
| CN112575003B (zh) * | 2020-12-17 | 2022-02-15 | 中国农业科学院植物保护研究所 | 本氏烟hakai基因在调控植物抗病毒中的应用及转基因植物培育方法 |
| CN112961247A (zh) * | 2020-12-17 | 2021-06-15 | 维亚生物科技(上海)有限公司 | 一种融合蛋白及其应用 |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| CN112630449B (zh) * | 2020-12-30 | 2022-10-18 | 广西壮族自治区水牛研究所 | 对水牛出生时间进行判断的血液外泌体标志物及其应用 |
| CN112763714B (zh) * | 2020-12-31 | 2022-07-01 | 徐州市中心医院 | 一种用于肝癌诊断的生物标志物及其检测方法 |
| CN112662680B (zh) * | 2020-12-31 | 2022-07-05 | 浙江大学 | 番茄黄化转绿基因SlRHBDD2及其应用 |
| CN112794901B (zh) * | 2021-01-08 | 2022-01-04 | 南通大学附属医院 | 一种抗smim15单克隆抗体及其应用 |
| CN112362432B (zh) * | 2021-01-12 | 2021-04-09 | 广州科方生物技术股份有限公司 | 一种通用于血清中tt3和tt4的解离剂及其制备方法 |
| CN114762694B (zh) * | 2021-01-13 | 2023-07-14 | 中国人民解放军军事科学院军事医学研究院 | 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用 |
| CN112626236A (zh) * | 2021-01-14 | 2021-04-09 | 华南农业大学 | 与奶牛乳腺上皮细胞凋亡相关的circRNA标志物及其应用 |
| CN112679596B (zh) * | 2021-01-15 | 2022-03-15 | 武汉大学 | 一种内收蛋白的抗原肽及其抗体与应用 |
| CN112574997B (zh) * | 2021-01-17 | 2023-07-21 | 楷拓生物科技(苏州)有限公司 | 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用 |
| CN112852698B (zh) * | 2021-01-30 | 2022-11-29 | 军事科学院军事医学研究院军事兽医研究所 | 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用 |
| CN112795642A (zh) * | 2021-02-09 | 2021-05-14 | 四川大学华西医院 | 鉴定家族性渗出性玻璃体视网膜病变伴/不伴小头畸形的引物及其应用 |
| AU2022221309A1 (en) * | 2021-02-09 | 2023-08-24 | Virginia Commonwealth University | Mini circular rna therapeutics and vaccines and methods of use thereof |
| CN116940571A (zh) * | 2021-03-15 | 2023-10-24 | 诺华股份有限公司 | 苯并异噁唑衍生物及其用途 |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| CN113373129B (zh) * | 2021-05-25 | 2022-07-26 | 湖北大学 | 一种原核生物来源的Mbp_Argonaute蛋白及其应用 |
| CN113393900B (zh) * | 2021-06-09 | 2022-08-02 | 吉林大学 | 基于改进Transformer模型的RNA状态推断研究方法 |
| CN115491369B (zh) * | 2021-06-18 | 2025-06-03 | 佛山热休生物技术有限公司 | Pdia3的表位肽及所述表位肽与热休克蛋白的复合物 |
| CN113450872B (zh) * | 2021-07-02 | 2022-12-02 | 南昌大学 | 磷酸化位点特异激酶的预测方法 |
| CN113687076B (zh) * | 2021-07-14 | 2024-03-01 | 郑州大学 | 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用 |
| AU2022348976A1 (en) * | 2021-07-23 | 2024-02-08 | Cassava Sciences, Inc. | Blood-based diagnostic assays for alzheimer's disease |
| WO2023014598A2 (en) * | 2021-08-03 | 2023-02-09 | Inflammatix, Inc. | Isothermal amplification-based diagnosis and treatment of acute infection |
| CN113846122B (zh) * | 2021-08-16 | 2023-08-25 | 中国医学科学院医学生物学研究所 | 一种过表达snca的腺相关病毒载体aav-snca、制备方法及其应用 |
| JP2024534120A (ja) | 2021-08-24 | 2024-09-18 | ビオンテック・ソシエタス・エウロパエア | インビトロ転写技術 |
| CN113533589B (zh) * | 2021-09-16 | 2021-12-17 | 天九再生医学(天津)科技有限公司 | 一种分析外泌体电荷异质性的方法 |
| CN114457052B (zh) * | 2021-09-17 | 2024-02-27 | 厦门大学 | 一种抗肿瘤的多肽组合物及其应用 |
| KR102691927B1 (ko) * | 2021-10-01 | 2024-08-06 | (주)케어젠 | 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도 |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| TW202333780A (zh) | 2021-11-29 | 2023-09-01 | 德商拜恩技術股份公司 | 冠狀病毒疫苗 |
| CN114134109B (zh) * | 2021-12-10 | 2023-01-24 | 广州远想生物科技股份有限公司 | Egf间充质干细胞外泌体的纯化方法 |
| EP4450628A4 (en) * | 2021-12-13 | 2025-10-22 | Sml Biopharm Co Ltd | NUCLEIC ACID EXPRESSION PLATFORM WITH INCREASED EXPRESSION EFFICIENCY |
| CN114262378B (zh) * | 2021-12-20 | 2023-03-24 | 南京诺唯赞生物科技股份有限公司 | 一种omt的单克隆抗体及其制备方法 |
| WO2023121937A1 (en) * | 2021-12-21 | 2023-06-29 | Amgen Inc. | Dcaf4l2-specific t-cell receptors |
| CN114276418B (zh) * | 2021-12-28 | 2024-06-25 | 中国科学技术大学 | 一种可用于调控微管、治疗脱髓鞘病变靶向治疗的rna |
| CN114350800B (zh) * | 2021-12-29 | 2024-03-19 | 中南大学湘雅医院 | Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用 |
| CN114410778B (zh) * | 2021-12-29 | 2024-03-19 | 中南大学湘雅医院 | Pf543在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用 |
| CN114384032B (zh) * | 2022-01-17 | 2023-07-14 | 云南大学 | 诺如病毒检测探针和非诊断目的检测诺如病毒的方法 |
| WO2023147091A1 (en) | 2022-01-28 | 2023-08-03 | BioNTech SE | Coronavirus vaccine |
| US20250108134A1 (en) * | 2022-01-28 | 2025-04-03 | Beijing Changping Laboratory | Circular rna vaccines and methods of use thereof |
| CN115058388A (zh) * | 2022-03-14 | 2022-09-16 | 福建医科大学附属协和医院 | 间充质干细胞创面修复优势功能亚群及其鉴定和应用 |
| CN114561389A (zh) * | 2022-03-15 | 2022-05-31 | 南通市肿瘤医院 | Vrk1表达抑制剂及其应用 |
| CN114621962B (zh) * | 2022-03-21 | 2024-05-14 | 广西大学 | 花生AhBI-1基因VIGS沉默体系 |
| US12416044B2 (en) * | 2022-03-21 | 2025-09-16 | Abclonal Science, Inc. | T4 DNA ligase variants with increased ligation efficiency |
| CN114410607A (zh) * | 2022-03-22 | 2022-04-29 | 上海威高医疗技术发展有限公司 | 嗜热羧酸酯酶突变体及其应用 |
| JP2025512965A (ja) * | 2022-04-07 | 2025-04-22 | アレタ・バイオセラピューティクス・インコーポレイテッド | がんの治療のための組成物及び方法 |
| US20250251394A1 (en) * | 2022-04-12 | 2025-08-07 | Concordia University | Aptamer-based electrochemical drug detection assay |
| CN115219720A (zh) * | 2022-05-20 | 2022-10-21 | 上饶师范学院 | 靶向分子atx在乙肝阳性肝癌中的应用及其研究方法 |
| CN114702569B (zh) * | 2022-05-25 | 2023-01-10 | 深圳吉诺因生物科技有限公司 | Pd-l1相关疫苗及其应用 |
| CN114703287B (zh) * | 2022-06-06 | 2022-08-12 | 江苏省肿瘤医院 | CXorf56基因在治疗三阴性乳腺癌中的应用 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN114916502B (zh) * | 2022-07-07 | 2023-06-16 | 电子科技大学 | 一种视网膜色素变性疾病模型的构建方法和应用 |
| CN116286990A (zh) * | 2022-09-08 | 2023-06-23 | 南开大学 | 特异性靶向肿瘤和转移抑制的细胞膜来源纳米囊泡的制备方法与应用 |
| EP4604995A1 (en) | 2022-10-17 | 2025-08-27 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| CN116254253B (zh) * | 2022-11-11 | 2024-06-28 | 浙大宁波理工学院 | 一种通过dna合成改组组合突变获得的谷氨酸脱羧酶突变体及应用 |
| CN115472216B (zh) * | 2022-11-14 | 2023-03-24 | 神州医疗科技股份有限公司 | 基于数据集成的肿瘤跨适应症联合用药推荐方法和系统 |
| CN116083353B (zh) * | 2022-12-02 | 2025-10-17 | 唐颐生物医学(天津)有限公司 | 一种过表达Anxa1的脐带间充质干细胞外泌体及其制备方法和应用 |
| CN115814605B (zh) * | 2022-12-06 | 2024-04-12 | 浙江大学 | 一种废弃反渗透膜修复剂及修复方法 |
| CN116271007B (zh) * | 2022-12-26 | 2025-10-03 | 浙江大学 | 一种用于治疗炎症性肠病的药物 |
| CN116236584B (zh) * | 2023-02-20 | 2024-03-22 | 四川大学 | 一种用于高效递送siRNA的多糖-多肽偶联物 |
| CN116334083B (zh) * | 2023-02-24 | 2025-06-20 | 青岛农业大学 | 花生U6启动子及其在花生CRISPR-Cas9基因编辑中的应用 |
| CN116474080B (zh) * | 2023-04-20 | 2023-12-22 | 新疆农垦科学院 | 一种细粒棘球绦虫表面展示型酿酒酵母口服疫苗及其构建方法和应用 |
| NL2034658B1 (en) * | 2023-04-21 | 2024-10-28 | Academisch Ziekenhuis Leiden | TIMP3-derived TEIPP neoantigens and uses thereof |
| CN116555286B (zh) * | 2023-04-28 | 2024-05-14 | 昆明理工大学 | 三七富含脯氨酸蛋白基因PnPRPL1及其应用 |
| US12502424B2 (en) | 2023-05-05 | 2025-12-23 | Sanofi Pasteur Inc. | Compositions for use in treatment of acne |
| CN116514115B (zh) * | 2023-05-05 | 2025-05-13 | 大连医科大学 | 一种巯基烟酸与金纳米粒子修饰氧化石墨烯材料及其制备方法和应用 |
| AU2024278682A1 (en) | 2023-05-26 | 2025-11-27 | CureVac SE | Cancer antigens |
| CN116637123B (zh) * | 2023-06-07 | 2024-02-13 | 上海市东方医院（同济大学附属东方医院） | 敲降或下调C15orf39基因表达的试剂在制备治疗胃癌的药物中的应用 |
| EP4484954A1 (en) * | 2023-06-29 | 2025-01-01 | Uniwersytet Gdanski | Mhc class i restricted immunopeptide pattern for generation of anti-nsclc vaccines |
| WO2025064738A1 (en) * | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| CN117169519B (zh) * | 2023-10-26 | 2024-01-30 | 艾康生物技术(杭州)有限公司 | 用于检测样本中tt3和/或tt4的解离剂和试剂盒 |
| CN117230077B (zh) * | 2023-11-13 | 2024-02-23 | 四川省医学科学院·四川省人民医院 | Hakai基因在RP疾病模型构建中的应用及构建方法 |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| US12515107B2 (en) | 2023-11-15 | 2026-01-06 | Acushnet Company | Multi-layer golf balls with in-situ adhesion promoter |
| WO2025131119A1 (en) * | 2023-12-22 | 2025-06-26 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
| WO2025140126A1 (en) * | 2023-12-25 | 2025-07-03 | Everest Medicines (China) Co., Ltd. | Therapeutic ly6k mrna vaccine for cancer |
| WO2025146130A1 (en) * | 2024-01-04 | 2025-07-10 | Everest Medicines (China) Co., Ltd. | Therapeutic BIRC5 mRNA Vaccine for Cancer |
| WO2025146077A1 (en) * | 2024-01-04 | 2025-07-10 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
| WO2025148611A1 (zh) * | 2024-01-12 | 2025-07-17 | 新牛（郑州）生物科技有限公司 | 肿瘤抗原肽融合蛋白及其组合物的基因工程化递送和应用 |
| CN117986344B (zh) * | 2024-02-05 | 2025-12-02 | 浙江大学 | 一种靶向线粒体核糖核酸酶p的多肽及应用 |
| CN118516398B (zh) * | 2024-02-26 | 2025-04-22 | 四川农业大学 | 水稻OsMED23基因、其编码蛋白及其应用 |
| CN118389553A (zh) * | 2024-03-01 | 2024-07-26 | 中国科学技术大学 | 免疫增效rna分子及其组合物、疫苗与试剂盒 |
| KR20250148433A (ko) * | 2024-03-29 | 2025-10-14 | 한미약품 주식회사 | 복수 kras 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도 |
| CN118006766B (zh) * | 2024-04-09 | 2024-06-28 | 鄂尔多斯市中心医院（内蒙古自治区超声影像研究所） | Pola2在诊断代谢综合征中的应用 |
| CN118546871B (zh) * | 2024-05-10 | 2025-05-06 | 未来智人再生医学研究院(广州)有限公司 | 一种人多能干细胞分化为间充质干细胞的方法 |
| WO2025242026A1 (en) * | 2024-05-20 | 2025-11-27 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
| WO2025242815A1 (en) | 2024-05-23 | 2025-11-27 | CureVac SE | Immunotherapy of squamous cell carcinoma |
| WO2025246436A1 (en) * | 2024-05-29 | 2025-12-04 | Therorna Inc. | Circular rna-based therapeutic vaccine for treating hpv positive cancer |
| CN118460649B (zh) * | 2024-07-10 | 2024-12-13 | 凯莱英医药集团（天津）股份有限公司 | 一种Vutrisiran的制备方法 |
| CN118530376B (zh) * | 2024-07-26 | 2024-11-26 | 英特菲尔(成都)生物制品有限责任公司 | 一种具有修复抗皱活性的弹性蛋白及其制备方法与应用 |
| CN119082106B (zh) * | 2024-07-30 | 2025-09-30 | 福建中医药大学 | 一种抑制pno1基因表达的核酸分子及相关产品和用途 |
| CN118879730B (zh) * | 2024-08-08 | 2025-03-21 | 宁波大学 | 小麦TaHAKAI基因在调控小麦黄花叶病抗性中的应用 |
| CN119464240B (zh) * | 2024-08-19 | 2025-11-07 | 浙江理工大学绍兴生物医药研究院有限公司 | 一种突变型高稳定的过氧化氢酶及其构建方法 |
| WO2026063308A1 (ja) * | 2024-09-17 | 2026-03-26 | 公益財団法人がん研究会 | 膀胱癌の検査方法 |
| CN119464217B (zh) * | 2024-11-01 | 2026-01-13 | 天津外泌体科技有限公司 | 一种囊泡及其作为标准品的应用 |
| CN119390756B (zh) * | 2024-11-04 | 2025-12-09 | 南京大学 | 一类基于d构型二苯丙氨酸的拟肽及其应用 |
| CN119120482B (zh) * | 2024-11-08 | 2025-02-14 | 中国医学科学院医学生物学研究所 | E3泛素连接酶rnf181基因表达抑制剂在制备预防和/或治疗hsv-1病毒感染药物中的应用 |
| CN119334929B (zh) * | 2024-11-19 | 2026-02-24 | 中元汇吉生物技术股份有限公司 | 一种提升磷酸化tau蛋白检测灵敏度的方法及其试剂盒 |
| CN121554551B (zh) * | 2026-01-20 | 2026-03-31 | 湖南益龄肿瘤科学研究院有限公司 | 抗癌活性糖蛋白及其制备方法、应用和抗女性癌症药物 |
Family Cites Families (173)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU649066B2 (en) | 1990-07-25 | 1994-05-12 | Syngene, Inc. | Circular extension for generating multiple nucleic acid complements |
| US5633234A (en) * | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| US5773244A (en) | 1993-05-19 | 1998-06-30 | Regents Of The University Of California | Methods of making circular RNA |
| AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
| US5534499A (en) | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| JP3734040B2 (ja) | 1996-06-14 | 2006-01-11 | 明治乳業株式会社 | Ｔ細胞エピトープペプチド |
| DE69840326D1 (de) * | 1997-03-27 | 2009-01-22 | Csl Ltd | Steigerung der immunantwort unter verwendung von zielgerichteten molekülen |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| CA2685270C (en) * | 1998-05-13 | 2014-07-29 | Pharmexa Inc. | Expression vectors for stimulating an immune response and methods of using the same |
| US6210931B1 (en) | 1998-11-30 | 2001-04-03 | The United States Of America As Represented By The Secretary Of Agriculture | Ribozyme-mediated synthesis of circular RNA |
| US7060284B1 (en) | 1999-08-03 | 2006-06-13 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
| ES2248283T3 (es) | 2000-02-21 | 2006-03-16 | Pharmexa A/S | Nuevo procedimiento para reducir los niveles de amiloide. |
| EP1363938B1 (en) | 2000-08-03 | 2013-12-11 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
| US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
| US20030091590A1 (en) | 2001-01-17 | 2003-05-15 | Pomerantz Roger J. | Recombinant rhabdoviruses as live-viral vaccines |
| DE60141773D1 (de) * | 2001-04-20 | 2010-05-20 | Inst Systems Biology | Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren |
| ATE490267T1 (de) | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| WO2004000873A2 (en) | 2002-06-25 | 2003-12-31 | City Of Hope | Adjuvant-free peptide vaccine |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| EP1572116A4 (en) * | 2002-11-26 | 2007-12-12 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| CU23204A1 (es) | 2002-12-27 | 2007-05-18 | Ct Ingenieria Genetica Biotech | Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| DE10347710B4 (de) * | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| KR20070122563A (ko) | 2005-04-19 | 2007-12-31 | 일라이 릴리 앤드 캄파니 | 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원 |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| EP3611266B1 (en) * | 2005-08-23 | 2022-11-09 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| BRPI0709340A2 (pt) * | 2006-03-27 | 2013-04-16 | Globeimmune, Inc. | mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma |
| EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2008157688A2 (en) | 2007-06-19 | 2008-12-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| EP2176408B9 (en) | 2008-01-31 | 2015-11-11 | Curevac GmbH | NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| EP2161279A1 (en) | 2008-08-29 | 2010-03-10 | Centre National de la Recherche Scientifique | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| ES2646630T3 (es) | 2008-11-07 | 2017-12-14 | Massachusetts Institute Of Technology | Lipidoides aminoalcohólicos y usos de los mismos |
| HUE037082T2 (hu) | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Új lipidek és készítmények terápiás hatóanyagok szállítására |
| WO2010087791A1 (en) | 2009-01-27 | 2010-08-05 | Utc Power Corporation | Distributively cooled, integrated water-gas shift reactor and vaporizer |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| US9764012B2 (en) * | 2009-04-01 | 2017-09-19 | University Of Miami | Vaccine compositions and methods of use thereof |
| US8467858B2 (en) | 2009-04-29 | 2013-06-18 | Tomophase Corporation | Image-guided thermotherapy based on selective tissue thermal treatment |
| KR20180094137A (ko) | 2009-05-05 | 2018-08-22 | 알닐람 파마슈티칼스 인코포레이티드 | 지질 조성물 |
| MX342785B (es) | 2009-06-10 | 2016-10-12 | Alnylam Pharmaceuticals Inc | Formulacion mejorada de lipido. |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| CN104959087B (zh) | 2010-04-09 | 2017-08-15 | 帕西拉制药有限公司 | 用于配制大直径合成膜囊泡的方法 |
| SG186085A1 (en) | 2010-06-03 | 2013-01-30 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| EP2590625B1 (en) | 2010-07-06 | 2017-09-20 | GlaxoSmithKline Biologicals SA | Cationic oil-in-water emulsions |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| PT3970742T (pt) | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| ES2727583T3 (es) | 2010-08-31 | 2019-10-17 | Glaxosmithkline Biologicals Sa | Lípidos adecuados para la administración liposómica de ARN que codifica proteínas |
| RS63890B1 (sr) | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Mali lipozomi za isporuku rnk koja kodira imunogen |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| US20140141070A1 (en) | 2011-07-06 | 2014-05-22 | Andrew Geall | Liposomes having useful n:p ratio for delivery of rna molecules |
| EP3549611B1 (en) * | 2011-07-29 | 2021-06-30 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
| EP3508220A1 (en) | 2011-08-31 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding rna |
| WO2013059475A1 (en) | 2011-10-18 | 2013-04-25 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| SG10201607962RA (en) * | 2012-03-27 | 2016-11-29 | Curevac Ag | Artificial nucleic acid molecules |
| RU2658490C2 (ru) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| WO2013143700A2 (en) | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| WO2013174409A1 (en) | 2012-05-25 | 2013-11-28 | Curevac Gmbh | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| RU2718988C2 (ru) | 2013-02-22 | 2020-04-15 | Куревак Аг | Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение |
| BR112016001192A2 (pt) | 2013-08-21 | 2017-08-29 | Curevac Ag | Vacina contra a raiva |
| DK3035955T3 (da) | 2013-08-21 | 2019-12-02 | Curevac Ag | Sammensætning og vaccine til behandling af lungekræft |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| WO2015024664A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Composition and vaccine for treating prostate cancer |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| US9593077B2 (en) | 2013-11-18 | 2017-03-14 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| WO2015100219A1 (en) | 2013-12-23 | 2015-07-02 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| KR102399799B1 (ko) | 2013-12-30 | 2022-05-18 | 큐어백 아게 | 인공 핵산 분자 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
| US11028143B2 (en) * | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
| CA2936286A1 (en) | 2014-04-01 | 2015-10-08 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US10837039B2 (en) | 2014-06-10 | 2020-11-17 | Curevac Real Estate Gmbh | Methods and means for enhancing RNA production |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| US10407683B2 (en) | 2014-07-16 | 2019-09-10 | Modernatx, Inc. | Circular polynucleotides |
| KR20250067191A (ko) * | 2014-09-17 | 2025-05-14 | 노파르티스 아게 | 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화 |
| DE202015010000U1 (de) | 2014-12-12 | 2023-07-03 | CureVac SE | Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression |
| CA2962849A1 (en) | 2014-12-16 | 2016-06-23 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
| KR102580696B1 (ko) | 2014-12-30 | 2023-09-19 | 큐어백 에스이 | 신규 인공 핵산 분자 |
| US20180000953A1 (en) | 2015-01-21 | 2018-01-04 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2016118725A1 (en) | 2015-01-23 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| EP3283059B1 (en) | 2015-04-13 | 2024-01-03 | CureVac Manufacturing GmbH | Method for producing rna compositions |
| SG11201707663SA (en) | 2015-04-17 | 2017-11-29 | Curevac Ag | Lyophilization of rna |
| RU2749113C2 (ru) | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| US20180208957A1 (en) | 2015-04-30 | 2018-07-26 | Curevac Ag | Method for in vitro transcription using an immobilized restriction enzyme |
| ES2897823T3 (es) | 2015-04-30 | 2022-03-02 | Curevac Ag | Poli(N)polimerasa inmovilizada |
| DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
| KR20180004820A (ko) | 2015-05-15 | 2018-01-12 | 큐어백 아게 | 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법 |
| EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
| WO2016184575A1 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
| PL4108769T3 (pl) | 2015-05-29 | 2024-02-05 | CureVac Manufacturing GmbH | Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym |
| EP4098743A1 (en) | 2015-05-29 | 2022-12-07 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
| US20180296663A1 (en) | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
| US20190017100A1 (en) | 2015-07-01 | 2019-01-17 | Curevac Ag | Method for analysis of an rna molecule |
| WO2017009376A1 (en) | 2015-07-13 | 2017-01-19 | Curevac Ag | Method of producing rna from circular dna and corresponding template dna |
| WO2017021546A1 (en) | 2015-08-05 | 2017-02-09 | Curevac Ag | Epidermal mrna vaccine |
| DK3332019T3 (da) | 2015-08-07 | 2020-02-17 | Curevac Ag | Fremgangsmåde til in vivo-produktionen af rna i en værtscelle |
| WO2017025447A1 (en) | 2015-08-10 | 2017-02-16 | Curevac Ag | Method of increasing the replication of a circular dna molecule |
| ES2964690T3 (es) | 2015-09-21 | 2024-04-09 | Trilink Biotechnologies Llc | Método para sintetizar ARN con caperuza 5' |
| US11225682B2 (en) | 2015-10-12 | 2022-01-18 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
| WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
| JP2018530587A (ja) | 2015-10-16 | 2018-10-18 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法 |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| WO2017070620A2 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| EP3374504B1 (en) | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
| US11413346B2 (en) | 2015-11-09 | 2022-08-16 | Curevac Ag | Rotavirus vaccines |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| US20180371392A1 (en) | 2015-12-21 | 2018-12-27 | Curevac Ag | Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
| EP3394280A1 (en) | 2015-12-23 | 2018-10-31 | CureVac AG | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| US9834510B2 (en) | 2015-12-30 | 2017-12-05 | Arcturus Therapeutics, Inc. | Aromatic ionizable cationic lipid |
| EP3414340B1 (en) | 2016-02-12 | 2023-08-09 | CureVac SE | Method for analyzing rna |
| WO2017140345A1 (en) | 2016-02-15 | 2017-08-24 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
| US11723967B2 (en) | 2016-02-17 | 2023-08-15 | CureVac SE | Zika virus vaccine |
| EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
| US20190177714A1 (en) | 2016-03-24 | 2019-06-13 | Curevac Ag | Immobilized inorganic pyrophosphatase (ppase) |
| US20180237789A1 (en) | 2016-04-16 | 2018-08-23 | Jiangnan University | Mortierella alpine uracil auxotroph with ura5 gene knocked out through homologous recombination |
| EP3777881A1 (en) | 2016-04-22 | 2021-02-17 | CureVac AG | Rna encoding a tumor antigen |
| WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| EP4631970A3 (en) | 2016-05-04 | 2026-01-07 | CureVac SE | Nucleic acid molecules and uses thereof |
| US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| EP4233898A3 (en) | 2016-05-04 | 2023-11-01 | CureVac SE | Influenza mrna vaccines |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| WO2017203008A1 (en) | 2016-05-25 | 2017-11-30 | Curevac Ag | Novel biomarkers |
| WO2017212009A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
| WO2017212006A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| WO2017212008A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| MX2019001920A (es) | 2016-08-19 | 2019-07-01 | Curevac Ag | Arn la terapia contra el cancer. |
| US11390899B2 (en) * | 2016-09-26 | 2022-07-19 | SOLA Biosciences, LLC | Cell-associated secretion-enhancing fusion proteins |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| BR112019008481A2 (pt) | 2016-10-26 | 2020-03-03 | Curevac Ag | Vacinas de mrna de nanopartículas lipídicas |
| RU2020103379A (ru) * | 2017-07-04 | 2021-08-04 | Куревак Аг | Новые молекулы нуклеиновых кислот |
-
2018
- 2018-07-03 RU RU2020103379A patent/RU2020103379A/ru unknown
- 2018-07-03 BR BR112019028280-7A patent/BR112019028280A2/pt unknown
- 2018-07-03 KR KR1020207003234A patent/KR102761594B1/ko active Active
- 2018-07-03 SG SG11201911430PA patent/SG11201911430PA/en unknown
- 2018-07-03 EP EP18181544.0A patent/EP3424524B1/en active Active
- 2018-07-03 US US16/026,729 patent/US10988754B2/en active Active
- 2018-07-03 ES ES18181544T patent/ES3013993T3/es active Active
- 2018-07-03 CN CN201880044741.6A patent/CN111328287A/zh active Pending
- 2018-07-03 JP JP2019572536A patent/JP7722629B2/ja active Active
- 2018-07-03 AU AU2018298422A patent/AU2018298422B2/en active Active
- 2018-07-03 WO PCT/EP2018/068015 patent/WO2019008001A1/en not_active Ceased
- 2018-07-03 EP EP24217588.3A patent/EP4494652A3/en active Pending
- 2018-07-03 CA CA3066932A patent/CA3066932A1/en active Pending
- 2018-07-03 EP EP18740528.7A patent/EP3648791A1/en not_active Withdrawn
-
2021
- 2021-03-15 US US17/201,764 patent/US20210198649A1/en active Pending
-
2023
- 2023-06-29 JP JP2023106624A patent/JP2023123739A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4494652A3 (en) | 2025-05-14 |
| JP2023123739A (ja) | 2023-09-05 |
| AU2018298422B2 (en) | 2023-04-06 |
| JP2020530980A (ja) | 2020-11-05 |
| CN111328287A (zh) | 2020-06-23 |
| JP7722629B2 (ja) | 2025-08-13 |
| SG11201911430PA (en) | 2020-01-30 |
| EP4494652A2 (en) | 2025-01-22 |
| EP3424524A3 (en) | 2019-02-27 |
| US20190040378A1 (en) | 2019-02-07 |
| EP3424524A2 (en) | 2019-01-09 |
| US20210198649A1 (en) | 2021-07-01 |
| ES3013993T3 (en) | 2025-04-16 |
| BR112019028280A2 (pt) | 2020-07-14 |
| CA3066932A1 (en) | 2019-01-10 |
| KR20200024905A (ko) | 2020-03-09 |
| WO2019008001A1 (en) | 2019-01-10 |
| EP3424524B1 (en) | 2024-12-11 |
| RU2020103379A3 (https=) | 2021-12-07 |
| AU2018298422A1 (en) | 2019-12-19 |
| KR102761594B1 (ko) | 2025-02-03 |
| US10988754B2 (en) | 2021-04-27 |
| EP3648791A1 (en) | 2020-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020103379A (ru) | Новые молекулы нуклеиновых кислот | |
| AU2019253562B2 (en) | Methods and compositions comprising a viral vector for expression of a transgene and an effector | |
| AU2025205077A1 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| US20220202863A1 (en) | Cells with multiplexed inhibitory rna | |
| LU92821B1 (en) | Combination comprising immunostimulatory oligonucleotides | |
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| CN112218651A (zh) | 用于与嵌合抗原受体疗法组合的免疫增强rna | |
| JPWO2019008001A5 (https=) | ||
| WO2017158019A1 (en) | A transposon-based transfection system for primary cells | |
| WO2010144295A1 (en) | Aptamer-targeted costimulatory ligand aptamer | |
| EP2491123A2 (en) | Single molecule nucleic acid nanoparticles | |
| CN116018406A (zh) | 改进的多重化抑制性rna支架 | |
| HUE027617T2 (en) | Universal tumor cell vaccine for therapeutic and prophylactic use | |
| WO2020163222A1 (en) | Nucleic acid sequence encoding chimeric antigen receptor and a short hairpin rna sequence for il-6 or a checkpoint inhibitor | |
| JP2024527322A (ja) | がんを治療するための組成物および方法 | |
| JP2021525067A5 (https=) | ||
| US20250127917A1 (en) | Compositions and methods for treating cancers | |
| CN110087665A (zh) | Tlr9靶向治疗 | |
| US11053503B2 (en) | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | |
| CA3226130A1 (en) | Compositions and methods for treating cancers | |
| JPWO2019226946A5 (https=) | ||
| CN117897178A (zh) | 用于治疗癌症的组合物和方法 | |
| JP2025500531A (ja) | 細胞改変のための系及び方法 | |
| CN121652286A (zh) | 一种调控nk细胞杀伤功能的三特异性衔接器及其应用 | |
| WO2023081767A1 (en) | Methods for immunotherapy |